Frontier Airlines added new Florida flights. Here's where, when and which ones cost $59
The low-fare airline launched six new routes from Hartsfield-Jackson Atlanta International Airport (ATL) on June 12 and 13, including twice-weekly flights to Jacksonville, Fort Myers and Palm Beach, the company said in a release. All three Florida routes will run twice a week.
The new route is part of Frontier's "America's Greenest Airline" promotion, with introductory fares as low as $59 for Sunshine State flights.
"We are thrilled to launch these additional six routes from ATL this week, including our first ever service to the beautiful country of Honduras – just the latest in our growth in Atlanta,' said Josh Flyr, vice president of network and operations design, Frontier Airlines.
Tickets for the listed flights must be purchased by 11:59 p.m. ET on June 25, 2025. Sale fares are valid for non-stop travel on select days of week, June 27, 2025, through Nov. 19, 2025. Blackout dates apply: July 3 and 6, 2025 and Sep. 1, 2025. A 14-day advance purchase is required. Round trip purchase is not required.
Jacksonville (JAX), starting June 12, 2025, 2x/week, starting at $59
Ft. Myers (RSW), starting June 12, 2025, 2x/week, starting at $59
Palm Beach (PBI), starting June 13, 2025, 2x/week, starting at $59
San Pedro Sula, Honduras (SAP), starting June 12, 2025, 2x/week, starting at $89
St. Louis (STL), starting June 12, 2025, 3x/week, starting at $69
Columbus, Ohio (CMH), starting June 13, 2025, 2x/week, starting at $49
Last year, the Colorado-based airline (with bases in Miami, Orlando and Tampa) responded to complaints from the traveling community with some big changes:
New fare bundles: Frontier overhauled its fare structure to simplify it and add more amenities
No change fee: All Frontier passengers (except for Basic ticketholders) will be able to cancel or change their tickets without having to pay an extra fee
Customer service phone line: After catching heat for dumping its customer service phone line in 2022, they brought it back
Low price guarantee: Frontier is offering 2,500 miles for any customer who finds a lower price for a comparable flight on another airline on the same route and date (details here)
New seating option with empty middle seat: Choosing the UpFront Plus option gets you a guaranteed empty middle seat so passengers sitting by the window or aisle have more personal space (more details)
This article originally appeared on Palm Beach Post: Frontier Airlines Florida flights added to Atlanta. Here's where
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Trump's tax law will mostly benefit the rich, while leaving poorer Americans with less, CBO says
WASHINGTON (AP) — President Donald Trump'stax and spending law will result in less income for the poorest Americans while sending money to the richest, the nonpartisan Congressional Budget Office reported Monday. The CBO estimates that the 10% of poorest Americans will lose roughly $1,200 a year as they experience restrictions on government programs like Medicaid and food assistance, while the richest 10% of Americans will see their income increase by $13,600 from tax cuts. Overall, American households will see more income from the tax cuts in the legislation, including middle income households, but the largest benefit will go to the top 10% of earners. The CBO's report comes as lawmakers are away from Washington, many taking their messages about the bill to voters. Republicans muscled the legislation — deemed 'the big, beautiful bill' by Trump — through Congress in July. Democrats all vehemently opposed the legislation, warning that its tax cuts and spending priorities would come at the expense of vital government aid programs and a ballooning national debt. 'This really is a big, beautiful bill for billionaires, but for the poor and the working class in this country, you are actually poorer,' said Rep. Brendan Boyle, the top Democrat on the House Budget Committee, in an MSNBC interview on Monday. Changes to eligibility for government food assistance under the law will impact millions of Americans, the CBO found. Roughly 2.4 million people won't be eligible for the Supplemental Nutrition Assistance Program under new work requirements for many recipients. Low-income Americans could also see their income reduced through further restrictions on food aid and other types of assistance included in the law. Already, more than 10 million Americans are expected to be without health insurance by 2034 due to changes to Medicaid under the law. Republicans were eager to sell the upsides of the legislation — arguing that the tax cuts will spur economic growth — while they are on a monthlong summer break from Washington. But those who have held townhalls in their home districts have often been greeted by an earful from voters and activists. 'Tax the rich,' the crowd in Lincoln, Neb. chanted last week as Republican Rep. Michael Flood attempted to defend the bill. Still, Trump has been undeterred. 'President Trump's One Big Beautiful Bill is putting America First like never before, delivering huge savings for hardworking families, boosting our economy, and securing our borders,' said White House deputy press secretary Abigail Jackson in a statement last week. Stephen Groves, The Associated Press
Yahoo
18 minutes ago
- Yahoo
Harrow Announces Second-Quarter 2025 Financial Results
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the 'Investors' section of its website, The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for the business. 'The second quarter provided a strong financial and operational foundation for the back half of the year,' said Mark L. Baum, Chief Executive Officer of Harrow. 'These results have positioned us to strengthen our capital base and are a proof point as to the financial leverage we believe our business has. We remain on track to deliver greater than $280 million in revenue for the year. 'VEVYE® continues to gain commercial momentum, adding nearly 3% in market share in the quarter, with 66% sequential prescription growth, including approximately 50,000 new prescriptions. Now, with an average selling price (ASP) that is stable with an upward bias over the coming quarters, we expect quarterly revenues to begin to expand meaningfully and exceed $100 million for 2025. Our VEVYE® Access for All (VAFA) program, which has significantly improved patient access and reduced barriers to treatment, is currently driving growth in prescription volumes for VEVYE, and we believe the recent expansion of our pharmacy network to include a full nationwide retail network should improve our ASP and further unlock VEVYE's commercial and financial potential. 'In addition, IHEEZO® has found its growth footing and is expected to deliver record performance through the balance of the year. TRIESENCE® volumes are improving, and with a coming launch in its largest market, ocular inflammation, we expect to finally demonstrate a revenue trajectory consistent with our original acquisition thesis – that TRIESENCE should eventually deliver $100 million in annual revenue. The balance of our branded portfolio, as well as ImprimisRx, our compounding business, are on track and delivering results in line with our 2025 forecast. Together, these results highlight strength, resilience, and growing demand for our ophthalmic disease management solutions. 'In sum, our commercial platform is firing on all cylinders – scaling rapidly and driving strong, growing profitability as demand surges for VEVYE and IHEEZO, and improves the rest of our portfolio. With powerful new revenue streams on deck – including the Samsung biosimilars portfolio, BYQLOVI™, and the expansion of TRIESENCE into its largest potential market – all with minimal incremental cost, we are poised to unlock additional operational leverage and deliver meaningful profitability for Harrow stockholders.' Business Highlights: Apollo Care Strategic Alliance for VAFA Harrow recently entered into a strategic alliance with Apollo Care, an innovative service provider for patient access and commercial solutions, as Harrow's second specialty pharmacy partner for the VAFA program. With 500+ pharmacies and full nationwide coverage, Apollo Care's pharmacy network is broadly contracted with major and small commercial, TRICARE and Medicare plans, positioning it to accelerate VAFA's expansion while driving broader insurance coverage. Samsung Bioepis In July 2025, Harrow secured the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEA (aflibercept) — two of the most widely used anti-VEGF therapies for retinal diseases. BYQLOVI Acquisition In June 2025, Harrow acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Second Quarter 2025 Financial Results: For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024 Total revenues $ 63,742,000 $ 48,939,000 $ 111,573,000 $ 83,526,000 Gross margin 75% 74% 72% 72% Core gross margin(1) 80% 79% 78% 78% Net income (loss) 4,995,000 (6,473,000 ) (12,785,000 ) (20,038,000 ) Core net income (loss)(1) 9,227,000 (2,047,000 ) (4,327,000 ) (11,836,000 ) Adjusted EBITDA(1) 17,006,000 8,803,000 15,021,000 9,030,000 Net income (loss) per share: Basic 0.14 (0.18 ) (0.35 ) (0.56 ) Diluted 0.13 (0.18 ) (0.35 ) (0.56 ) Core net income (loss) per share:(1) Basic 0.25 (0.06 ) (0.12 ) (0.33 ) Diluted 0.24 (0.06 ) (0.12 ) (0.33 ) (1) Core gross margin, core net income (loss), core basic and diluted net income (loss) per share (collectively, 'Core Results'), and Adjusted EBITDA are non-GAAP measures. For additional information, including a reconciliation of such Core Results and Adjusted EBITDA to the most directly comparable measures presented in accordance with GAAP, see the explanation of non-GAAP measures and reconciliation tables at the end of this release. Conference Call and Webcast Participants can access the live webcast of Harrow's presentation on the 'Investors' page of Harrow's website. A replay of the webcast will be available on the Company's website for one year. To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call. About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such 'forward--looking statements.' Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, refinance and otherwise service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking- statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking- statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Contact:Mike Biega, VP of Investor Relations and Communications mbiega@ HARROW, CONSOLIDATED BALANCE SHEETS June 30,2025 December 31,2024 (unaudited) ASSETS Cash and cash equivalents $ 52,963,000 $ 47,247,000 All other current assets 101,927,000 142,404,000 Total current assets 154,890,000 189,651,000 All other assets 190,143,000 199,320,000 TOTAL ASSETS $ 345,033,000 $ 388,971,000 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities $ 248,884,000 $ 91,343,000 Loans payable, net of unamortized debt discount and current portion 38,484,000 219,539,000 All other liabilities 8,366,000 8,792,000 TOTAL LIABILITIES 295,734,000 319,674,000 TOTAL STOCKHOLDERS' EQUITY 49,299,000 69,297,000 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 345,033,000 $ 388,971,000 HARROW, CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024 Total revenues $ 63,742,000 $ 48,939,000 $ 111,573,000 $ 83,526,000 Cost of sales 16,230,000 12,539,000 31,754,000 23,092,000 Gross profit 47,512,000 36,400,000 79,819,000 60,434,000 Selling, general and administrative 33,235,000 31,817,000 73,748,000 60,630,000 Research and development 2,868,000 3,053,000 5,894,000 5,202,000 Total operating expenses 36,103,000 34,870,000 79,642,000 65,832,000 Income (loss) from operations 11,409,000 1,530,000 177,000 (5,398,000 ) Total other expense, net (6,414,000 ) (7,348,000 ) (12,962,000 ) (13,985,000 ) Income tax expense - 655,000 - 655,000 Net income (loss) attributable to Harrow, Inc. $ 4,995,000 $ (6,473,000 ) $ (12,785,000 ) $ (20,038,000 ) Net income (loss) per share: Basic $ 0.14 $ (0.18 ) $ (0.35 ) $ (0.56 ) Diluted $ 0.13 $ (0.18 ) $ (0.35 ) $ (0.56 ) HARROW, CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Six Months EndedJune 30, 2025 2024 Net cash provided by (used in): Operating activities $ 18,865,000 $ (7,374,000 ) Investing activities (505,000 ) 4,993,000 Financing activities (12,644,000 ) (736,000 ) Net change in cash and cash equivalents 5,716,000 (3,117,000 ) Cash and cash equivalents at beginning of the period 47,247,000 74,085,000 Cash and cash equivalents at end of the period $ 52,963,000 $ 70,968,000 Non-GAAP Financial Measures In addition to the Company's results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA and Core Results, unaudited financial measures that are not calculated in accordance with GAAP, to evaluate the Company's financial results and performance and to plan and forecast future periods. Adjusted EBITDA and Core Results are considered 'non-GAAP' financial measures within the meaning of Regulation G promulgated by the SEC. Management believes that these non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results, provide a more complete understanding of the Company's results of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA and Core Results provide meaningful supplemental information regarding the Company's performance because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) they exclude the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company's core operating performance and that may obscure trends in the Company's core operating performance; and (iii) they are used by institutional investors and the analyst community to help analyze the Company's results. However, Adjusted EBITDA, Core Results, and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company's competitors. Adjusted EBITDA The Company defines Adjusted EBITDA as net income (loss), excluding the effects of stock-based compensation and expenses, interest, taxes, depreciation, amortization, investment loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss) as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs. The following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net income (loss), for the three months and six months ended June 30, 2025 and for the same period in 2024: HARROW, OF NET LOSS TO ADJUSTED EBITDA For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024 GAAP net income (loss) $ 4,995,000 $ (6,473,000 ) $ (12,785,000 ) $ (20,038,000 ) Stock-based compensation and expenses 875,000 4,271,000 5,431,000 8,440,000 Interest expense, net 6,408,000 5,471,000 12,956,000 10,886,000 Income tax expense - 655,000 - 655,000 Depreciation 496,000 453,000 961,000 885,000 Amortization of intangible assets 4,226,000 2,549,000 8,452,000 5,103,000 Investment loss, net - 1,923,000 - 3,171,000 Other expense (income), net 6,000 (46,000 ) 6,000 (72,000 ) Adjusted EBITDA $ 17,006,000 $ 8,803,000 $ 15,021,000 $ 9,030,000 Core Results Harrow Core Results, including core gross margin, core net income (loss), and core basic and diluted income (loss) per share exclude (1) all amortization and impairment charges of intangible assets, excluding software development costs, (2) net gains and losses on investments and equity securities, including equity method gains and losses and equity valued at fair value through profit and loss (FVPL), and preferred stock dividends, and (3) gains/losses on forgiveness of debt. In certain periods, Core Results may also exclude fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, obligations related to product recalls, certain acquisition-related items, restructuring charges/releases and associated items, related legal items, gains/losses on early extinguishment of debt or debt modifications, impairments of property, plant and equipment and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a $100,000 threshold. The following is a reconciliation of Core Results, non-GAAP measures, to the most comparable GAAP measures for the three months and six months ended June 30, 2025 and 2024: For the Three Months Ended June 30, 2025 GAAPResults Amortizationof Certain Intangible Assets InvestmentGains(Losses) OtherItems CoreResults Gross profit $ 47,512,000 $ 3,780,000 $ - $ - $ 51,292,000 Gross margin 75 % 80 % Operating income 11,409,000 4,226,000 - - 15,635,000 Income before taxes 4,995,000 4,226,000 - 6,000 9,227,000 Taxes - - - - - Net income 4,995,000 4,226,000 - 6,000 9,227,000 Income per share ($)(1): Basic 0.14 0.25 Diluted 0.13 0.24 Weighted average number of shares of common stock outstanding: Basic 36,790,306 36,790,306 Diluted 38,853,855 38,853,855 For the Six Months Ended June 30, 2025 GAAPResults Amortizationof Certain Intangible Assets InvestmentGains(Losses) OtherItems CoreResults Gross profit $ 79,819,000 $ 7,560,000 $ - $ - $ 87,379,000 Gross margin 72 % 78 % Operating income 177,000 8,452,000 - - 8,629,000 Loss before taxes (12,785,000 ) 8,452,000 6,000 (4,327,000 ) Taxes - - - - - Net loss (12,785,000 ) 8,452,000 - 6,000 (4,327,000 ) Basic and diluted loss per share ($)(1) (0.35 ) (0.12 ) Weighted average number of shares of common stock outstanding, basic and diluted 36,304,787 36,304,787 For the Three Months Ended June 30, 2024 GAAPResults Amortization of Certain Intangible Assets InvestmentGains(Losses) OtherItems CoreResults Gross profit $ 36,400,000 $ 2,140,000 $ - $ - $ 38,540,000 Gross margin 74 % 79 % Operating income 1,530,000 2,549,000 - - 4,079,000 (Loss) income before taxes (5,818,000 ) 2,549,000 1,923,000 (46,000 ) (1,392,000 ) Taxes (655,000 ) - - - (655,000 ) Net (loss) income (6,473,000 ) 2,549,000 1,923,000 (46,000 ) (2,047,000 ) Basic and diluted loss per share ($)(1) (0.18 ) (0.06 ) Weighted average number of shares of common stock outstanding, basic and diluted 35,618,977 35,618,977 For the Six Months Ended June 30, 2024 GAAPResults Amortizationof Certain Intangible Assets InvestmentGains(Losses) OtherItems CoreResults Gross profit $ 60,434,000 $ 4,280,000 $ - $ - $ 64,714,000 Gross margin 72 % 78 % Operating loss (5,398,000 ) 5,103,000 - - (295,000 ) (Loss) income before taxes (19,383,000 ) 5,103,000 3,171,000 (72,000 ) (11,181,000 ) Taxes (655,000 ) - - - (655,000 ) Net (loss) income (20,038,000 ) 5,103,000 3,171,000 (72,000 ) (11,836,000 ) Basic and diluted loss per share ($)(1) (0.56 ) (0.33 ) Weighted average number of shares of common stock outstanding, basic and diluted 35,544,312 35,544,312 (1) Core basic and diluted loss per share is calculated using the weighted-average number of shares of common stock outstanding during the period. Core basic and diluted loss per share also contemplates dilutive shares associated with equity based awards as described in Note 2 and elsewhere in the Consolidated Financial Statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Los Angeles Times
19 minutes ago
- Los Angeles Times
Kayne Anderson BDC Announces Investment in Southern California Credit Platform SG Credit Partners
Kayne Anderson BDC Inc., a business development company externally managed by its investment adviser, KA Credit Advisors LLC, which is an affiliate of Kayne Anderson Capital Advisors LP, announced an investment in SG Credit Partners Inc., a Southern California-based national credit platform focused on the lower middle market. SG Credit was formed in 2013 and has offices in Newport Beach and Santa Monica, along with regional offices in Atlanta, Boston and Chicago. It has invested in more than 200 companies, originating over $1 billion in commitments across its three lending verticals (commercial finance, consumer products and software & technology). It plans to use its expanded capital base to grow existing verticals and develop adjacent businesses. 'This is a key strategic opportunity for KBDC and highlights our commitment to growing our portfolio with value-enhancing investments,' said Doug Goodwillie, co-chief executive of KBDC, in a statement. 'SG Credit's unique lower middle market lending platform is highly complementary to our business and will further enhance the returns of KBDC's diversified portfolio.' The investment complements KBDC's private credit investment capabilities by further diversifying proprietary investment channels and will be structured as an $80-million term loan facility, $34-million delayed draw term loan facility and $12-million common equity investment. KBDC anticipates that its debt investment in SG Credit will be immediately accretive to earnings in 2025, and it will be a significant minority shareholder in SG Credit following the closing of the transaction. 'We are proud and excited to partner with a firm of the caliber and history of Kayne Anderson. This collaboration will not only support our growth with additional capital but also enable us to offer innovative, value-added financing solutions to a wider range of companies,' said Marc Cole, co-founder and chief executive of SG Credit, in a statement. Fenchurch Advisory Partners US LP served as financial advisor and Mayer Brown LLP as legal advisor to KBDC. Solomon Partners served as financial advisor and Greenberg Traurig LLP and Brenner, Saltzman & Wallman LLP as legal advisors to SG Credit. Information for this article was sourced from Kayne Anderson BDC.
